The atrophy and changes in the cellular compositions of the thymus and spleen observed in mice subjected to short-term exposure to perfluorooctanesulfonate are high-dose phenomena mediated in part by peroxisome proliferator-activated receptor-alpha (PPARα)

Toxicology

Volumn 260, Issue 1-3, 2009, Pages 68-76

  Qazi, Mousumi Rahman ^a   Xia, Zhenlei ^a   Bogdanska, Jasna ^a   Chang, Shu Ching ^b   Ehresman, Dave J ^b   Butenhoff, John L ^b   Nelson, B Dean ^a   DePierre, Joseph W ^a   Abedi Valugerdi, Manuchehr ^a  

^a STOCKHOLM UNIVERSITY   (Sweden)

^b 3M COMPANY   (United States)

Author keywords

Immunotoxicity; Perfluorooctanesulfonate; Perfluorooctanoate; Peroxisome proliferator activated receptor alpha; Spleen; Thymus

Indexed keywords

PERFLUOROOCTANESULFONIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATROPHY; C57BL 6 MOUSE; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMPOSITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FLOW CYTOMETRY; HEPATOMEGALY; HISTOPATHOLOGY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; KNOCKOUT GENE; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SPLEEN; SPLEEN CELL; THYMOCYTE; THYMUS; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT REDUCTION;

ALKANESULFONIC ACIDS; ANIMALS; ATROPHY; B-LYMPHOCYTES; BODY WEIGHT; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FLOW CYTOMETRY; FLUOROCARBONS; IMMUNOPHENOTYPING; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; OCTANOIC ACIDS; ORGAN SIZE; PPAR ALPHA; SPLEEN; T-LYMPHOCYTES; THYMUS GLAND;

ANIMALIA; MUS;

EID: 67349112418     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2009.03.009     Document Type: Article

References (58)

1. 3M Company, 2003. Environmental and Health Assessment of Perfluorooctanesulfonate and its Salts. 3M Company, August 20, 2003. U.S. EPA docket AR-226-1486. U.S. Environmental Protection Agency, Washington, DC.
2. Alexander B.H., and Olsen G.W. Bladder cancer in perfluorooctanesulfonyl fluoride manufacturing workers. Ann. Epidemiol. 17 (2007) 471-478 (Epub April 19, 2007)
3. Alexander B.H., Olsen G.W., Burris J.M., Mandel J.H., and Mandel J.S. Mortality of employees of a perfluorooctanesulphonyl fluoride manufacturing facility. Occup. Environ. Med. 60 (2003) 722-729
4. Andersen M.E., Butenhoff J.L., Chang S.C., Farrar D.G., Kennedy Jr. G.L., Lau C., Olsen G.W., Seed J., and Wallace K.B. Perfluoroalkyl acids and related chemistries-toxicokinetics and modes of action. Toxicol. Sci. 102 (2008) 3-14
5. Andersen M.E., Clewell III H.J., Tan Y.M., Butenhoff J.L., and Olsen G.W. Pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacids in monkeys-probing the determinants of long plasma half-lives. Toxicology 227 (2006) 156-164
6. Asakawa A., Toyoshima M., Harada K.H., Fujimiya M., Inoue K., and Koizumi A. The ubiquitous environmental pollutant perfluorooctanoicacid inhibits feeding behavior via peroxisome proliferator-activated receptor-alpha. Int. J. Mol. Med. 21 (2008) 439-445
7. Blom K.G., Qazi M.R., Matos J.B., Nelson B.D., DePierre J.W., and Abedi-Valugerdi M. Isolation of murine intrahepatic immune cells employing a modified procedure for mechanical disruption and functional characterization of the B, T and natural killer T cells obtained. Clin. Exp. Immunol. 155 (2009) 320-329
8. Butenhoff J., Costa G., Elcombe C., Farrar D., Hansen K., Iwai H., Jung R., Kennedy, Lieder P., Olsen G., and Thomford P. Toxicity of ammonium perfluorooctanoate in male cynomolgus monkeys after oral dosing for 6 months. Toxicol. Sci. 69 (2002) 244-257
9. Butenhoff J.L., Gaylor D.W., Moore J.A., Olsen G.W., Rodricks J., Mandel J.H., and Zobel L.R. Characterization of risk for general population exposure to perfluorooctanoate. Regul. Toxicol. Pharmacol. 39 (2004) 363-380
10. Butenhoff J.L., Olsen G.W., and Pfahles-Hutchens A. The applicability of biomonitoring data for perfluorooctanesulfonate to the environmental public health continuum. Environ. Health Perspect. 114 (2006) 1776-1782
11. Calafat A.M., Kuklenyik Z., Reidy J.A., Caudill S.P., Tully J.S., and Needham L.L. Serum concentrations of 11 polyfluoroalkyl compounds in the U.S. population: data from the national health and nutrition examination survey (NHANES). Environ. Sci. Technol. 41 (2007) 2237-2242
12. DeWitt J.C., Shnyra A., Badr M.Z., Loveless S.E., Hoban D., Frame S.R., Cunard R., Anderson S.E., Meade B.J., Peden-Adams M.M., Luebke R.W., and Luster M.I. Immunotoxicity of perfluorooctanoic acid and perfluorooctane sulfonate and the role of peroxisome proliferator-activated receptor alpha. Crit. Rev. Toxicol. 39 (2009) 76-94
13. Ehresman D.J., Froehlich J.W., Olsen G.W., Chang S.C., and Butenhoff J.L. Comparison of human whole blood, plasma, and serum matrices for the determination of perfluorooctanesulfonate (PFOS), perfluorooctanoate (PFOA), and other fluorochemicals. Environ. Res. 103 (2007) 176-184 (Epub August 8, 2006)
14. Emmett E.A., Zhang H., Shofer F.S., Freeman D., Rodway N.V., Desai C., and Shaw L.M. Community exposure to perfluorooctanoate: relationships between serum levels and certain health parameters. J. Occup. Environ. Med. 48 (2006) 771-779
15. Giesy J.P., and Kannan K. Global distribution of perfluorooctane sulfonate in wildlife. Environ. Sci. Technol. 35 (2001) 1339-1342
16. Hishinuma K., Nishimura T., Konno A., Hashimoto Y., and Kimura S. Augmentation of mouse immune functions by dietary restriction: an investigation up to 1 year of age. Ann. Nutr. Metab. 34 (1990) 76-84
17. Houde M., Wells R.S., Fair P.A., Bossart G.D., Hohn A.A., Rowles T.K., Sweeney J.C., Solomon K.R., and Muir D.C. Polyfluoroalkyl compounds in free-ranging bottlenose dolphins (Tursiops truncatus) from the Gulf of Mexico and the Atlantic Ocean. Environ. Sci. Technol. 39 (2005) 6591-6598
18. Kannan K., Corsolini S., Falandysz J., Oehme G., Focardi S., and Giesy J.P. Perfluorooctanesulfonate and related fluorinated hydrocarbons in marine mammals, fishes, and birds from coasts of the Baltic and the Mediterranean Seas. Environ. Sci. Technol. 36 (2002) 3210-3216
19. Kannan K., Corsolini S., Falandysz J., Fillmann G., Kumar K.S., Loganathan B.G., Mohd M.A., Olivero J., Van Wouwe N., Yang J.H., and Aldoust K.M. Perfluorooctanesulfonate and related fluorochemicals in human blood from several countries. Environ. Sci. Technol. 38 (2004) 4489-4495
20. Keil D.E., Mehlmann T., Butterworth L., and Peden-Adams M.M. Gestational exposure to perfluorooctanoate sulfonate suppresses immune function in B6C3F1 mice. Toxicol. Sci. 103 (2008) 77-85
21. Kennedy Jr. G.L., Butenhoff J.L., Olsen G.W., O'Connor J.C., Seacat A.M., Perkins R.G., Biegel L.B., Murphy S.R., and Farrar D.G. The toxicology of perfluorooctanoate. Crit. Rev. Toxicol. 34 (2004) 351-384
22. Klaunig J.E., Babich M.A., Baetcke K.P., Cook J.C., Corton J.C., David R.M., DeLuca J.G., Lai D.Y., McKee R.H., Peters J.M., Roberts R.A., and Fenner-Crisp P.A. PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit. Rev. Toxicol. 33 (2003) 655-780
23. Kuklenyik Z., Reich J.A., Tully J.S., Needham L.L., and Calafat A.M. Automated solid-phase extraction and measurement of perfluorinated organic acids and amides in human serum and milk. Environ. Sci. Technol. 38 (2004) 3698-3704
24. Lau C., Anitole K., Hodes C., Lai D., Pfahles-Hutchens A., and Seed J. Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol. Sci. 99 (2007) 366-394
25. Lau C., Thibodeaux J.R., Hanson R.G., Rogers J.M., Grey B.E., Stanton M.E., Butenhoff J.L., and Stevenson L.A. Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. II. Postnatal evaluation. Toxicol. Sci. 74 (2003) 382-392
26. Lau C., Butenhoff J.L., and Rogers J.M. The developmental toxicity of perfluoroalkyl acids and their derivatives. Toxicol. Appl. Pharmacol. 198 (2004) 231-241
27. Lee S.S., Pineau T., Drago J., Lee E.J., Owens J.W., Kroetz D.L., Fernandez-Salguero P.M., Westphal H., and Gonzalez F.J. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 15 (1995) 3012-3022
28. Lefebvre D.E., Curran I., Armstrong C., Coady L., Parenteau M., Liston V., Barker M., Aziz S., Rutherford K., Bellon-Gagnon R., Shenton J., Mehta R., and Bondy G. Immunomodulatory effects of dietary potassium perfluorooctane sulfonate (PFOS) exposure in adult Sprague-Dawley rats. J. Toxicol. Environ. Health 71 Part A (2008) 1516-1525
29. Luebker D.J., Case M.T., York R.G., Moore J.A., Hansen K.J., and Butenhoff J.L. Two-generation reproduction and cross-foster studies of perfluorooctanesulfonate (PFOS) in rats. Toxicology 215 (2005) 126-148
30. Luebker D.J., York R.G., Hansen K.J., Moore J.A., and Butenhoff J.L. Neonatal mortality from in utero exposure to perfluorooctanesulfonate (PFOS) in Sprague-Dawley rats: dose-response, and biochemical and pharamacokinetic parameters. Toxicology 215 (2005) 149-169
31. Martin II L.B., Navara K.J., Bailey M.T., Hutch C.R., Powell N.D., Sheridan J.F., and Nelson R.J. Food restriction compromises immune memory in deer mice (Peromyscus maniculatus) by reducing spleen-derived antibody-producing B cell numbers. Physiol. Biochem. Zool. 81 (2008) 366-372
32. Martin J.W., Ellis D.A., Mabury S.A., Hurley M.D., and Wallington T.J. Atmospheric chemistry of perfluoroalkanesulfonamides: kinetic and product studies of the OH radical and Cl atom initiated oxidation of N-ethyl perfluorobutanesulfonamide. Environ. Sci. Technol. 40 (2006) 864-872
33. OECD. Hazard Assessment of Perfluorooctane Sulfonate (PFOS) and its Salts (2002), Organisation for Economic Cooperation and Development, Paris, France
34. Olsen G.W., Burris J.M., Burlew M.M., and Mandel J.H. Epidemiologic assessment of worker serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) concentrations and medical surveillance examinations. J. Occup. Environ. Med. 45 (2003) 260-270
35. Olsen G.W., Church T.R., Miller J.P., Burris J.M., Hansen K.J., Lundberg J.K., Armitage J.B., Herron R.M., Medhdizadehkashi Z., Nobiletti J.B., O'Neill E.M., Mandel J.H., and Zobel L.R. Perfluorooctanesulfonate and other fluorochemicals in the serum of American Red Cross adult blood donors. Environ. Health Perspect. 111 (2003) 1892-1901
36. Olsen G.W., Church T.R., Hansen K.J., Burris J.M., Butenhoff J.L., Mandel J.H., and Zobel L.R. Quantitative evaluation of perfluorooctanesulfonate (PFOS) and other fluorochemicals in the serum of children. J. Child. Health 2 (2004) 53-76
37. Olsen G.W., and Zobel L.R. Assessment of lipid, hepatic, and thyroid parameters with serum perfluorooctanoate (PFOA) concentrations in fluorochemical production workers. Int. Arch. Occup. Environ. Health 81 (2007) 231-246
38. Olsen G.W., Burris J.M., Ehresman D.J., Froehlich J.W., Seacat A.M., Butenhoff J.L., and Zobel L.R. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ. Health Perspect. 115 (2007) 1298-1305
39. Olsen G.W., Mair D.C., Reagen W.K., Ellefson M.E., Ehresman D.J., Butenhoff J.L., and Zobel L.R. Preliminary evidence of a decline in perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) concentrations in American Red Cross blood donors. Chemosphere 68 (2007) 105-111
40. Paustenbach D.J., Panko J.M., Scott P.K., and Unice K.M. A methodology for estimating human exposure to perfluorooctanoic acid (PFOA): a retrospective exposure assessment of a community (1951-2003). J. Toxicol. Environ. Health A 70 (2007) 28-57
41. Peden-Adams M.M., Keller J.M., Eudaly J.G., Berger J., Gilkeson G.S., and Keil D.E. Suppression of humoral immunity in mice following exposure to perfluorooctane sulfonate. Toxicol. Sci. 104 (2008) 144-154
42. Peters J.M., Lee S.S., Li W., Ward J.M., Gavrilova O., Everett C., Reitman M.L., Hudson L.D., and Gonzalez F.J. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta (delta). Mol. Cell. Biol. 20 (2000) 5119-5128
43. Peters L.L., Robledo R.F., Bult C.J., Churchill G.A., Paigen B.J., and Svenson K.L. The mouse as a model for human biology: a resource guide for complex trait analysis. Nat. Rev. Genet. 8 (2007) 58-69
44. Poetschke H.L., Klug D.B., Perkins S.N., Wang T.T., Richie E.R., and Hursting S.D. Effects of calorie restriction on thymocyte growth, death and maturation. Carcinogenesis 21 (2000) 1959-1964
45. Racanelli V., and Rehermann B. The liver as an immunological organ. Hepatology 43 Suppl. 1 (2006) 54-62
46. Renner R. Concerns over common perfluorinated surfactant. Environ. Sci. Technol. 37 (2003) 201A-202A
47. Savino W. The thymus gland is a target in malnutrition. Eur. J. Clin. Nutr. 56 Suppl. 3 (2002) 46-49
48. Seacat A.M., Thomford P.J., Hansen K.J., Olsen G.W., Case M.T., and Butenhoff J.L. Subchronic toxicity studies on perfluorooctanesulfonate potassium salt in cynomolgus monkeys. Toxicol. Sci. 68 (2002) 249-264
49. Seacat A.M., Thomford P.J., Hansen K.J., Clemen L.A., Eldridge S.R., Elcombe C.R., and Butenhoff J.L. Sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats. Toxicology 183 (2003) 117-131
50. Takacs M.L., and Abbott B.D. Activation of mouse and human peroxisome proliferator-activated receptors (alpha, beta/delta, gamma) by perfluorooctanoic acid and perfluorooctane sulfonate. Toxicol. Sci. 95 (2007) 108-117
51. Thibodeaux J.R., Hanson R.G., Rogers J.M., Grey B.E., Barbee B.D., Richards J.H., Butenhoff J.L., Stevenson L.A., and Lau C. Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. I. Maternal and prenatal evaluations. Toxicol. Sci. 74 (2003) 369-381
52. Vanden Heuvel J.P., Kuslikis B.I., Van Rafelghem M.J., and Peterson R.E. Tissue distribution, metabolism, and elimination of perfluorooctanoic acid in male and female rats. J. Biochem. Toxicol. 6 (1991) 83-92
53. Xie Y., Yang Q., Nelson B.D., and DePierre J.W. Characterization of the adipose tissue atrophy induced by peroxisome proliferators in mice. Lipids 37 (2002) 139-146
54. Xu L., Krenitsky D.M., Seacat A.M., Butenhoff J.L., Tephly T.R., and Anders M.W. N-glucuronidation of perfluorooctanesulfonamide by human, rat, dog, and monkey liver microsomes and by expressed rat and human UDP-glucuronosyltransferases. Drug Metab. Dispos. 34 (2006) 1406-1410
55. Yang Q., Xie Y., and Depierre J.W. Effects of peroxisome proliferators on the thymus and spleen of mice. Clin. Exp. Immunol. 122 (2000) 219-226
56. Yang Q., Xie Y., Eriksson A.M., Nelson B.D., and DePierre J.W. Further evidence for the involvement of inhibition of cell proliferation and development in thymic and splenic atrophy induced by the peroxisome proliferator perfluorooctanoic acid in mice. Biochem. Pharmacol. 62 (2001) 1133-1140
57. Yang Q., Xie Y., Alexson S.E., Nelson B.D., and DePierre J.W. Involvement of the peroxisome proliferator-activated receptor alpha in the immunomodulation caused by peroxisome proliferators in mice. Biochem. Pharmacol. 63 (2002) 1893-1900
58. Yang Q., Abedi-Valugerdi M., Xie Y., Zhao X.Y., Moller G., Nelson B.D., and DePierre J.W. Potent suppression of the adaptive immune response in mice upon dietary exposure to the potent peroxisome proliferator, perfluorooctanoic acid. Int. Immunopharmacol. 2 (2002) 389-397